title: Meningioma: current treatment options and future directions.
abstract: Benign meningiomas can be observed if not symptomatic or growing. When treatment is indicated, the options are surgery, radiosurgery, fractionated radiation therapy, or a combination of these modalities. Except in certain cases, such as large tumors that require debulking for relief of symptoms, we do not recommend the routine use of combination therapy. Intracranial meningiomas have usually been treated with surgical resection with an expected durable local control of 80% to 90% when a gross total resection (GTR) is obtained. Patients who have inoperable disease, refuse surgery, undergo less than a GTR, or who have aggressive histology should instead be considered candidates for radiation therapy or radiosurgery. While benign meningiomas can be successfully treated definitively or postoperatively with either fractionated radiation therapy or single fraction radiosurgery, atypical or malignant lesions are best treated with fractionated radiation therapy with conventional dosimetric margins. The role of systemic therapy is not yet defined, but multiple agents are being investigated in early phase trials for patients with recurrent or progressive disease after standard therapy has failed.
authors.affiliation: Comprehensive Cancer Center of Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157, USA. kmcmulle@wfubmc.edu
authors.forename: Kevin P
authors.initials: KP
authors.lastname: McMullen
authors.forename: Volker W
authors.initials: VW
authors.lastname: Stieber
mesh_terms: D003131:Combined Modality Therapy / Q000639:trends; D004032:Diet; D004632:Emergency Medical Services; D066246:ErbB Receptors / Q000819:agonists; D005544:Forecasting; D006801:Humans; D008019:Life Style; D008577:Meningeal Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D008579:Meningioma / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D008600:Menstruation-Inducing Agents / Q000627:therapeutic use; D015735:Mifepristone / Q000627:therapeutic use; D010982:Platelet-Derived Growth Factor / Q000819:agonists; D017410:Practice Guidelines as Topic
chemical_list: D008600:Menstruation-Inducing Agents; D010982:Platelet-Derived Growth Factor; D015735:Mifepristone; D066246:ErbB Receptors